Leading Edge Genomic Services & Solutions

PAG 2018

Ready for sunny San Diego? We are excited to see you at PAG 2018!
As a leading provider of genomic services and solutions, we are dedicated to providing fast turnaround time for projects of any size with the world’s largest NGS capacity at our state-of-the-art US sequencing lab at highly competitive prices!
See below for some highlighted services for animal and plant research!

Highlighted Services for PAG Attendees

RNA Sequencing

Learn More

Plant & Animal Whole Genome Sequencing

Learn More

PacBio Sequel Based de novo Sequencing

Learn More

Novogene Advantages

  • Rich experience: successfully sequenced >370,000 samples for >10,000 global customers
  • Quick turnaround time: finish projects in as fast as 2 weeks
  • Diverse sequencing platforms: access to 30 HiSeq X, 25 NovaSeq and 20 PacBio Sequel, the largest sequencing capacity in the world
  • Advanced data analysis for projects of all sizes
  • State-of-the-art California lab in the US, and branches worldwide

RNA Seq Promotion PAG

 

RNA-Seq at $199/Sample
World’s Largest Capacity
25 NovaSeq 6000, 30 HiSeq X, and 20 PacBio Sequel

Highest Quality Data & Affordable Prices
Q30 ≥ 80% guaranteed

Industry’s Best Prices
Also check out our Whole Genome Sequencing service on HiSeq X Ten

contact us

novaseq 6000

Celebrating the Arrival of NovaSeq at Novogene’s California Lab

 

RNA-Seq at $199/Sample
World’s Largest Capacity
25 NovaSeq 6000, 30 HiSeq X, and 20 PacBio Sequel

High Quality Data & Affordable Prices
Our latest NovaSeq systems enable highly affordable RNA-Seq and exome sequencing services with fast turnaround. See our Exome Sequencing Promotion!

Substantial discount available for a full NovaSeq flow cell (>1000 GB)

Also check out our Whole Genome Sequencing service on HiSeq X Ten

contact us

novaseq 6000

Marketing/Lead Generation Specialist (San Diego, CA)

Location: San Diego, CA

The Marketing Specialist will conduct market research and competitive analysis to guide product positioning, pricing, and sales strategies; represent the company to attend trade shows and company sponsored events; organize/generate sales leads; develop marketing collateral and sales tools; and establish our web presence to boost brand awareness.

Benefits:
Competitive salary and benefits including health, dental and vision insurance and 401k

Click here to download a pdf copy of the job description/requirements.

If you’re interested in applying for this position, please send your resume or CV to nana.li@novogene.com

Yi-Hsiang Hsu, M.D., ScD

Yi Hsiang

Yi-Hsiang Hsu, M.D., ScD

Director of the Genetic Epi Program, HSL Institute for Aging Research Beth Israel Deaconess Medical Center and Harvard Medical School

Dr. Yi-Hsiang Hsu is the Director of the Genetic Epi Program at HSL Institute for Aging Research and Harvard Medical School. He is a faculty at the Broad Institute of MIT and Harvard, as well as at Harvard Medical School and at Program for Quantitative Genomics, Program of Molecular and Integrative Physiological Sciences, Harvard School of Public Health, Boston, MA. 

Dr. Hsu is a Statistical Geneticist/Computational Biologist. His research focuses on (1) Genetic contribution of common aging relevant disorders (such as osteoporosis, sarcopenic obesity, metabolic syndrome, type 2 diabetes and hypertension) using population-based next generation (NGS) whole genome sequencing, exome-sequencing and genome-wide association (GWAS) approaches to identify common and rare variants that are associated with these complex traits/phenotypes; (2) Predicting non-coding causal variants and targeted genes in GWAS loci using tissue-and cell-specific gene regulatory landscapes generated by ENCODE and US NIH Roadmap Epigenomics Project; (3) Statistical method development on multiple-phenotype association analyses; (4) Integrating omics data (genomics, transcriptome, epigenomics, proteomics and metabolomics) using system genetics and bioinfomatic approaches; and (5) Identifying biomarkers of osteoporosis using metabolomics.

Xiao Dong, Ph.D.

Xiao Dong

Xiao Dong, Ph.D.

Postdoc Research Fellow, Jan Vijg Laboratory, Department of Genetics, Albert Einstein College of Medicine; Co-founder, SingulOmics Corporation

Dr. Dong received his Ph.D. at Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences in China in 2013, mentored by Dr. Yixue Li. From 2013 to now, he receives postdoc training at the laboratory of Dr. Jan Vijg at Department of Genetics, Albert Einstein College of Medicine in New York. He co-founded SingulOmics Corporation, a genomic research and service company specializing in the emerging field of single-cell omics, in 2016.

Dr. Dong developed multiple bioinformatic tools for analyzing DNA mutations, including the first method for analyzing somatic single nucleotide variations from normal primary single cells. He also applied computational methods on discovering the mechanisms of aging and age-related diseases. He has published more than 15 first or co-first author scientific research articles in top-tier journals including Nature, Nature Methods, Nature Communications, Genome Biology, Bioinformatics, Stem Cell Reports, Aging Cell, and Diabetes.

Michael Snyder, Ph.D.

Michael Snyder

Michael Snyder, Ph.D.

Stanford W. Ascherman Professor and Chair, Department of Genetics Director, Center for Genomics and Personalized Medicine, Stanford University

Dr. Snyder received his Ph.D. training at the California Institute of Technology and carried out postdoctoral training at Stanford University. He is a leader in the field of functional genomics and proteomics, and one of the major participants of the ENCODE project. His laboratory study was the first to perform a large-scale functional genomics project in any organism, and has developed many technologies in genomics and proteomics. These including the development of proteome chips, high resolution tiling arrays for the entire human genome, methods for global mapping of transcription factor binding sites (ChIP-chip now replaced by ChIP-seq), paired end sequencing for mapping of structural variation in eukaryotes, de novo genome sequencing of genomes using high throughput technologies and RNA-Seq. These technologies have been used for characterizing genomes, proteomes and regulatory networks. Seminal findings from the Snyder laboratory include the discovery that much more of the human genome is transcribed and contains regulatory information than was previously appreciated, and a high diversity of transcription factor binding occurs both between and within species. He has also combined different state-of–the-art “omics” technologies to perform the first longitudinal detailed integrative personal omics profile (iPOP) of person and used this to assess disease risk and monitor disease states for personalized medicine. He is a cofounder of several biotechnology companies, including Protometrix (now part of Life Technologies), Affomix (now part of Illumina), Excelix, and Personalis, and he presently serves on the board of a number of companies.